Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
59 studies found for:    (HIV infections) [CONDITION] AND vaccine [TREATMENT] | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
(HIV infections) [CONDITION] AND vaccine [TREATMENT] | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Conditions: Pneumococcal Vaccines;   HIV;   HIV Infections
Intervention: Biological: Prevenar and Pneumo23
2 Unknown  Preparing for Adolescent HIV Vaccine Trials in South Africa:
Conditions: HIV Infection;   HIV Infections
Intervention:
3 Recruiting Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Conditions: Anal Cancer;   Nonneoplastic Condition;   Penile Cancer;   Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: laboratory biomarker analysis
4 Not yet recruiting Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
Condition: HIV Infection
Interventions: Biological: LIPO-5;   Biological: MVA HIV-B (MVATG17401);   Biological: GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
5 Not yet recruiting Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo for DNA/NYVAC/AIDSVAX
6 Not yet recruiting Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123;   Biological: NYVAC-HIV-PT1;   Biological: NYVAC-HIV-PT4;   Biological: AIDSVAX B/E®;   Biological: Placebo vaccine
7 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
8 Unknown  Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients
Condition: HIV
Intervention: Biological: Sci-B-Vac
9 Recruiting Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Biological: HIVAX;   Biological: saline solution;   Biological: Saline solution
10 Unknown  Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
11 Recruiting The Safety and Immunogenicity of a Potential HIV Vaccine
Condition: HIV Infections
Intervention: Biological: CN54gp140 mixed with GLA-AF
12 Recruiting Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Conditions: HIV Infection;   HIV Seronegativity
Intervention:
13 Unknown  Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
Conditions: HPV;   HIV
Intervention: Biological: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
14 Recruiting Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults
Conditions: Influenza;   HIV;   Tuberculosis
Intervention: Biological: Trivalent Inactivated Influenza Vaccine
15 Unknown  Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects
Condition: HIV Infection
Intervention: Biological: Hepavax-Gene
16 Recruiting Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study
Condition: Acquired Immune Deficiency Syndrome Virus
Intervention: Biological: Live attenuated Vaccine- Fluenz Tretra
17 Recruiting Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
Condition: Healthy
Interventions: Biological: Ad26.Mos.HIV;   Biological: MVA-Mosaic;   Biological: gp140 DP Low-dose;   Biological: gp140 DP High-dose;   Drug: Placebo
18 Recruiting A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination
Conditions: Hepatitis C Infection;   HIV Infection
Interventions: Biological: AdCh3NSmut1;   Biological: MVA-NSmut;   Biological: ChAdV63.HIVconsv;   Biological: MVA.HIVconsv
19 Recruiting Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
Conditions: Solid Organ Transplant Recipient (Liver, Kidney, Heart);   Rheumatologic Disorder;   Human Immunodeficiency Virus (HIV);   Bone Marrow Transplant (BMT);   Dialysis
Interventions: Biological: Fluzone High Dose;   Biological: Fluzone
20 Recruiting Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS
Condition: Acquired Immunodeficiency Syndrome
Interventions: Biological: Saline Solution;   Biological: D-GPEi;   Biological: M-GPE

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years